vs

Side-by-side financial comparison of POTLATCHDELTIC CORP (PCH) and QuidelOrtho Corp (QDEL). Click either name above to swap in a different company.

QuidelOrtho Corp is the larger business by last-quarter revenue ($619.8M vs $314.2M, roughly 2.0× POTLATCHDELTIC CORP). POTLATCHDELTIC CORP runs the higher net margin — 8.2% vs -14.8%, a 23.1% gap on every dollar of revenue. On growth, POTLATCHDELTIC CORP posted the faster year-over-year revenue change (23.1% vs -10.5%). Over the past eight quarters, POTLATCHDELTIC CORP's revenue compounded faster (11.1% CAGR vs -6.6%).

PotlatchDeltic Corporation is an American diversified forest products company based in Spokane, Washington.

QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.

PCH vs QDEL — Head-to-Head

Bigger by revenue
QDEL
QDEL
2.0× larger
QDEL
$619.8M
$314.2M
PCH
Growing faster (revenue YoY)
PCH
PCH
+33.7% gap
PCH
23.1%
-10.5%
QDEL
Higher net margin
PCH
PCH
23.1% more per $
PCH
8.2%
-14.8%
QDEL
Faster 2-yr revenue CAGR
PCH
PCH
Annualised
PCH
11.1%
-6.6%
QDEL

Income Statement — Q3 FY2025 vs Q1 FY2027

Metric
PCH
PCH
QDEL
QDEL
Revenue
$314.2M
$619.8M
Net Profit
$25.9M
$-91.8M
Gross Margin
18.2%
Operating Margin
11.2%
Net Margin
8.2%
-14.8%
Revenue YoY
23.1%
-10.5%
Net Profit YoY
682.5%
EPS (diluted)
$0.33
$-1.35

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PCH
PCH
QDEL
QDEL
Q1 26
$619.8M
Q3 25
$314.2M
$699.9M
Q2 25
$275.0M
$613.9M
Q1 25
$268.3M
$692.8M
Q4 24
$258.1M
$707.8M
Q3 24
$255.1M
$727.1M
Q2 24
$320.7M
$637.0M
Q1 24
$228.1M
$711.0M
Net Profit
PCH
PCH
QDEL
QDEL
Q1 26
$-91.8M
Q3 25
$25.9M
$-733.0M
Q2 25
$7.4M
$-255.4M
Q1 25
$25.8M
$-12.7M
Q4 24
$5.2M
$-178.4M
Q3 24
$3.3M
$-19.9M
Q2 24
$13.7M
$-147.7M
Q1 24
$-305.0K
$-1.7B
Gross Margin
PCH
PCH
QDEL
QDEL
Q1 26
Q3 25
18.2%
Q2 25
13.0%
Q1 25
17.8%
Q4 24
13.4%
Q3 24
10.8%
Q2 24
11.9%
Q1 24
7.0%
Operating Margin
PCH
PCH
QDEL
QDEL
Q1 26
Q3 25
11.2%
-100.7%
Q2 25
5.0%
-29.4%
Q1 25
10.3%
4.7%
Q4 24
5.2%
-14.2%
Q3 24
2.8%
2.1%
Q2 24
5.4%
-18.4%
Q1 24
-2.1%
-247.3%
Net Margin
PCH
PCH
QDEL
QDEL
Q1 26
-14.8%
Q3 25
8.2%
-104.7%
Q2 25
2.7%
-41.6%
Q1 25
9.6%
-1.8%
Q4 24
2.0%
-25.2%
Q3 24
1.3%
-2.7%
Q2 24
4.3%
-23.2%
Q1 24
-0.1%
-239.9%
EPS (diluted)
PCH
PCH
QDEL
QDEL
Q1 26
$-1.35
Q3 25
$0.33
$-10.78
Q2 25
$0.09
$-3.77
Q1 25
$0.33
$-0.19
Q4 24
$0.07
$-2.54
Q3 24
$0.04
$-0.30
Q2 24
$0.17
$-2.20
Q1 24
$0.00
$-25.50

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PCH
PCH
QDEL
QDEL
Cash + ST InvestmentsLiquidity on hand
$88.8M
$140.4M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$1.9B
$1.9B
Total Assets
$3.2B
$5.6B
Debt / EquityLower = less leverage
1.33×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PCH
PCH
QDEL
QDEL
Q1 26
$140.4M
Q3 25
$88.8M
$98.1M
Q2 25
$95.3M
$151.7M
Q1 25
$147.5M
$127.1M
Q4 24
$151.6M
$98.3M
Q3 24
$161.1M
$143.7M
Q2 24
$199.7M
$107.0M
Q1 24
$180.2M
$78.5M
Total Debt
PCH
PCH
QDEL
QDEL
Q1 26
$2.5B
Q3 25
$2.5B
Q2 25
$2.1B
Q1 25
$2.1B
Q4 24
$1.0B
$2.1B
Q3 24
$2.2B
Q2 24
$2.2B
Q1 24
$2.2B
Stockholders' Equity
PCH
PCH
QDEL
QDEL
Q1 26
$1.9B
Q3 25
$1.9B
$2.0B
Q2 25
$1.9B
$2.8B
Q1 25
$2.0B
$3.0B
Q4 24
$2.0B
$3.0B
Q3 24
$2.1B
$3.2B
Q2 24
$2.1B
$3.2B
Q1 24
$2.2B
$3.3B
Total Assets
PCH
PCH
QDEL
QDEL
Q1 26
$5.6B
Q3 25
$3.2B
$5.7B
Q2 25
$3.2B
$6.4B
Q1 25
$3.3B
$6.5B
Q4 24
$3.3B
$6.4B
Q3 24
$3.3B
$6.8B
Q2 24
$3.4B
$6.7B
Q1 24
$3.4B
$6.7B
Debt / Equity
PCH
PCH
QDEL
QDEL
Q1 26
1.33×
Q3 25
1.23×
Q2 25
0.74×
Q1 25
0.70×
Q4 24
0.51×
0.72×
Q3 24
0.68×
Q2 24
0.70×
Q1 24
0.68×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PCH
PCH
QDEL
QDEL
Operating Cash FlowLast quarter
$65.7M
Free Cash FlowOCF − Capex
$50.1M
FCF MarginFCF / Revenue
15.9%
Capex IntensityCapex / Revenue
4.9%
Cash ConversionOCF / Net Profit
2.54×
TTM Free Cash FlowTrailing 4 quarters
$132.4M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PCH
PCH
QDEL
QDEL
Q1 26
Q3 25
$65.7M
$-45.5M
Q2 25
$41.0M
$-46.8M
Q1 25
$49.1M
$65.6M
Q4 24
$45.4M
$63.7M
Q3 24
$26.5M
$117.9M
Q2 24
$100.6M
$-97.9M
Q1 24
$16.0M
$-700.0K
Free Cash Flow
PCH
PCH
QDEL
QDEL
Q1 26
Q3 25
$50.1M
$-94.7M
Q2 25
$30.6M
$-84.3M
Q1 25
$26.3M
$9.4M
Q4 24
$25.4M
$16.5M
Q3 24
$-8.2M
$71.4M
Q2 24
$72.4M
$-133.2M
Q1 24
$2.0M
$-66.8M
FCF Margin
PCH
PCH
QDEL
QDEL
Q1 26
Q3 25
15.9%
-13.5%
Q2 25
11.1%
-13.7%
Q1 25
9.8%
1.4%
Q4 24
9.9%
2.3%
Q3 24
-3.2%
9.8%
Q2 24
22.6%
-20.9%
Q1 24
0.9%
-9.4%
Capex Intensity
PCH
PCH
QDEL
QDEL
Q1 26
Q3 25
4.9%
7.0%
Q2 25
3.8%
6.1%
Q1 25
8.5%
8.1%
Q4 24
7.7%
6.7%
Q3 24
13.6%
6.4%
Q2 24
8.8%
5.5%
Q1 24
6.1%
9.3%
Cash Conversion
PCH
PCH
QDEL
QDEL
Q1 26
Q3 25
2.54×
Q2 25
5.58×
Q1 25
1.90×
Q4 24
8.74×
Q3 24
7.99×
Q2 24
7.35×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PCH
PCH

Lumber$131.8M42%
Timberlands$52.5M17%
Rural Real Estate$51.3M16%
Residuals And Panels$34.0M11%
Pulpwood$16.7M5%
Development Real Estate$14.6M5%
Other$8.1M3%
Other Products$5.2M2%

QDEL
QDEL

Labs$353.1M57%
Immunohematology$138.3M22%
Point of Care$112.8M18%
Molecular Diagnostics$7.8M1%

Related Comparisons